DE69927520T2 - Verwendung von il-12 antikörpern zur behandlung von psoriasis - Google Patents

Verwendung von il-12 antikörpern zur behandlung von psoriasis Download PDF

Info

Publication number
DE69927520T2
DE69927520T2 DE69927520T DE69927520T DE69927520T2 DE 69927520 T2 DE69927520 T2 DE 69927520T2 DE 69927520 T DE69927520 T DE 69927520T DE 69927520 T DE69927520 T DE 69927520T DE 69927520 T2 DE69927520 T2 DE 69927520T2
Authority
DE
Germany
Prior art keywords
mice
cells
scid
disease
ifnγ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927520T
Other languages
German (de)
English (en)
Other versions
DE69927520D1 (de
Inventor
Rolf Ehrhardt
Kenneth Hong
Cary Queen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69927520(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of DE69927520D1 publication Critical patent/DE69927520D1/de
Application granted granted Critical
Publication of DE69927520T2 publication Critical patent/DE69927520T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
DE69927520T 1998-12-09 1999-12-08 Verwendung von il-12 antikörpern zur behandlung von psoriasis Expired - Lifetime DE69927520T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11164298P 1998-12-09 1998-12-09
US111642P 1998-12-09
PCT/US1999/029123 WO2000034459A1 (en) 1998-12-09 1999-12-08 Animal model for psoriasis for the prevention and treatment of psoriasis in humans

Publications (2)

Publication Number Publication Date
DE69927520D1 DE69927520D1 (de) 2006-02-09
DE69927520T2 true DE69927520T2 (de) 2006-06-22

Family

ID=22339643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927520T Expired - Lifetime DE69927520T2 (de) 1998-12-09 1999-12-08 Verwendung von il-12 antikörpern zur behandlung von psoriasis

Country Status (10)

Country Link
US (5) US6410824B1 (cg-RX-API-DMAC7.html)
EP (2) EP1336654A1 (cg-RX-API-DMAC7.html)
JP (2) JP3579355B2 (cg-RX-API-DMAC7.html)
AT (1) ATE305506T1 (cg-RX-API-DMAC7.html)
AU (1) AU1843200A (cg-RX-API-DMAC7.html)
CA (1) CA2353520C (cg-RX-API-DMAC7.html)
DE (1) DE69927520T2 (cg-RX-API-DMAC7.html)
DK (1) DK1137766T3 (cg-RX-API-DMAC7.html)
ES (1) ES2251248T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000034459A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706264B1 (en) * 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
US20060171890A1 (en) * 2005-01-28 2006-08-03 Yeomans David C Methods for evaluating the activity of candidate agents
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
WO2008088823A2 (en) * 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US20110002918A1 (en) * 2009-03-06 2011-01-06 Photomedex Methods of treating diseased tissue
ES2352929B1 (es) 2009-08-14 2012-01-26 Centro De Investigaciones Energeticas. Medioamb Ientales Y Tecnologicas (Ciemat) Modelo humanizado de psoriasis
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
TW201242976A (en) * 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
WO2018008902A1 (ko) * 2016-07-05 2018-01-11 성균관대학교산학협력단 건선 유발 동물 모델 및 이의 용도
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191870A (en) * 1937-08-14 1940-02-27 Wayne Pump Co Liquid dispensing apparatus
US2224256A (en) * 1938-08-05 1940-12-10 Baker Chem Co J T Pharmaceutical preparation
US2297692A (en) * 1939-08-15 1942-10-06 Bendix Aviat Corp Fluid flywheel control
US2275692A (en) * 1940-04-02 1942-03-10 Sims Edward Airplane aileron
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
NL8700927A (nl) 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
IT1231727B (it) 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
CA2070416A1 (en) * 1989-10-23 1991-04-24 Richard Ingram Polypeptide inhibitors of gamma interferon
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
CA2148907C (en) * 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US6706264B1 (en) * 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
JPH08289699A (ja) * 1995-04-24 1996-11-05 Chemo Sero Therapeut Res Inst 自己免疫疾患モデル動物及びその作製方法
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US5945576A (en) 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
WO1997037679A1 (en) * 1996-04-10 1997-10-16 Board Of Trustees Of The University Of Illinois Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
WO1998016248A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ES2206981T3 (es) * 1997-07-17 2004-05-16 F.Hoffmann-La Roche Ag Dihomo-seco-colestanos con dos enlaces insaturados en la cadena lateral.
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
KR100764256B1 (ko) 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
WO2000032634A1 (en) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing

Also Published As

Publication number Publication date
US20020194631A1 (en) 2002-12-19
EP1137766A1 (en) 2001-10-04
JP4671265B2 (ja) 2011-04-13
WO2000034459A1 (en) 2000-06-15
EP1137766B1 (en) 2005-09-28
AU1843200A (en) 2000-06-26
JP2004231667A (ja) 2004-08-19
CA2353520C (en) 2006-04-25
ATE305506T1 (de) 2005-10-15
JP2002531123A (ja) 2002-09-24
ES2251248T3 (es) 2006-04-16
EP1137766A4 (en) 2002-08-14
US6410824B1 (en) 2002-06-25
DK1137766T3 (da) 2006-01-30
EP1336654A1 (en) 2003-08-20
JP3579355B2 (ja) 2004-10-20
US20030056233A1 (en) 2003-03-20
DE69927520D1 (de) 2006-02-09
US9078876B2 (en) 2015-07-14
US20130071388A1 (en) 2013-03-21
US20140314756A1 (en) 2014-10-23
US9072725B2 (en) 2015-07-07
CA2353520A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE69501817T2 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
EP1137766B1 (en) Use of il-12 antibodies to treat psoriasis
Khoruts et al. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells
DE69634782T2 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
DE69032484T2 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
DE69624116T3 (de) Verfahren zur behandlung von allergischem asthma
DE69621918T4 (de) Medikamente zur behandlung von autoimmunerkrankungen mit interferon-tau
DE60123238T2 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE69230862T2 (de) Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
DE60125961T2 (de) Modulierung einer allergischen antwort
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE68908431T2 (de) Methode zur Verminderung der Immunglobulin-E-Reaktion.
DE19505287A1 (de) Zusammensetzung und Verfahren zur Prävention und Behandlung von Entzündungen mit Immunglobulin A
EP2004692B1 (de) Behandlung von multipler sklerose und/oder rheumatoider arthritis mittels anti-ccr2 antikörpern
DE69310182T2 (de) Interleukin-4 stimulierter t-lymphozyten-zelltod
DE69821506T2 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
DE69813070T2 (de) Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex
DE69533311T2 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69728654T2 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE10157290A1 (de) Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
DE69929712T2 (de) Antagonisten des Alpha-E-Beta-7 Integrins als therapeutische Agenzien gegen Entzündungskrankheiten
EP1235592B1 (de) Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
DE69227918T2 (de) VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PDL BIOPHARMA, INC. (N.D.GES.D. STAATES DELAWARE),

8327 Change in the person/name/address of the patent owner

Owner name: FACET BIOTECH CORP., REDWOOD CITY, CALIF., US

R082 Change of representative

Ref document number: 1137766

Country of ref document: EP

Representative=s name: HUBER & SCHUESSLER, 81825 MUENCHEN, DE

R082 Change of representative

Ref document number: 1137766

Country of ref document: EP

Representative=s name: ,

R081 Change of applicant/patentee

Ref document number: 1137766

Country of ref document: EP

Owner name: ABBVIE BIOTHERAPEUTICS INC., US

Free format text: FORMER OWNER: ABBOTT BIOTHERAPEUTICS CORP., REDWOOD CITY, US

Effective date: 20121213